Αποτελέσματα Αναζήτησης
Our results indicate that splint therapy effectively reduces pain levels in TMDSD patients, and reduces the frequency of pain inpatients with TMJ clicking. Additionally, splint therapy increased mouth opening ability in patients with initial MMO < 45mm.
- Oral splints for patients with temporomandibular disorders or bruxism ...
This evidence synthesis compared (1) all types of splint...
- Oral splints for patients with temporomandibular disorders or bruxism ...
14 Φεβ 2020 · Objectives To evaluate the clinical-effectiveness of oral splints for patients with TMD or bruxism for the primary outcomes: pain (TMD) and tooth wear (bruxism). Data sources Four databases...
This evidence synthesis compared (1) all types of splint versus no/minimal treatment/control splints and (2) prefabricated versus custom-made splints, for the primary outcomes, which were pain (temporomandibular disorders) and tooth wear (bruxism).
1 Ιαν 2023 · Occlusal splints are beneficial for reducing tension, decreasing muscle activity, and preventing harmful effects caused by bruxism and temporomandibular disorders (TMDs). Treatment options for TMDs include reassurance, patient education, occlusal splint therapy, or physiotherapy.
16 Μαΐ 2019 · During 6-month period, SS was more effective than PS in reducing spontaneous pain and improving self-perceived quality of life and functional limitations of the lower jaw. Moreover, significantely higher values of pain-free mouth opening were observed in patients treated with stabilization splint.
In contrast to our study, Kurita et al. instructed their patients to use splints 24 hours per day, and they concluded that splint therapy had a 60–70% success rate treating symptoms such as TMJ pain, maximal mouth opening, and masticatory muscle pain, with a poor success rate for TMJ noise and disk derangement symptoms. They provided no ...
20 Δεκ 2016 · Thirteen eligible studies involving 538 patients were identified. The results indicated that splint therapy increased maximal mouth opening (MMO) for patients with a MMO <45mm and reduced pain intensity measured using the visual analogue scale (VAS) for patients with TMD without specific description (TMDSD).
